Operations and Assets for Operating Segments and Geographic Information |
Information regarding our operations and assets for our operating segments and the unallocated corporate operations as well as geographic information are as follows:
|
|
|
|
|
|
|
|
|
|
For the three months ended March 31, |
(In thousands) |
2019 |
|
2018 |
Revenue from services: |
|
|
|
Pharmaceutical |
$ |
— |
|
|
$ |
— |
|
Diagnostics |
178,891 |
|
|
211,315 |
|
Corporate |
— |
|
|
— |
|
|
$ |
178,891 |
|
|
$ |
211,315 |
|
Revenue from products: |
|
|
|
Pharmaceutical |
$ |
25,301 |
|
|
$ |
27,851 |
|
Diagnostics |
— |
|
|
— |
|
Corporate |
— |
|
|
— |
|
|
$ |
25,301 |
|
|
$ |
27,851 |
|
Revenue from transfer of intellectual property and other: |
|
|
|
Pharmaceutical |
$ |
18,259 |
|
|
$ |
15,748 |
|
Diagnostics |
— |
|
|
— |
|
Corporate |
— |
|
|
— |
|
|
$ |
18,259 |
|
|
$ |
15,748 |
|
Operating loss: |
|
|
|
Pharmaceutical |
$ |
(29,477 |
) |
|
$ |
(22,948 |
) |
Diagnostics |
(33,569 |
) |
|
(8,018 |
) |
Corporate |
(12,272 |
) |
|
(11,645 |
) |
|
$ |
(75,318 |
) |
|
$ |
(42,611 |
) |
Depreciation and amortization: |
|
|
|
Pharmaceutical |
$ |
7,526 |
|
|
$ |
6,740 |
|
Diagnostics |
16,271 |
|
|
17,987 |
|
Corporate |
19 |
|
|
30 |
|
|
$ |
23,816 |
|
|
$ |
24,757 |
|
Loss from investment in investees: |
|
|
|
Pharmaceutical |
$ |
(1,854 |
) |
|
$ |
(2,172 |
) |
Diagnostics |
— |
|
|
(284 |
) |
Corporate |
— |
|
|
— |
|
|
$ |
(1,854 |
) |
|
$ |
(2,456 |
) |
Revenues: |
|
|
|
United States |
$ |
184,894 |
|
|
$ |
215,311 |
|
Ireland |
20,534 |
|
|
17,282 |
|
Chile |
7,865 |
|
|
11,733 |
|
Spain |
4,418 |
|
|
5,532 |
|
Israel |
3,116 |
|
|
3,614 |
|
Mexico |
1,531 |
|
|
1,420 |
|
Other |
93 |
|
|
22 |
|
|
$ |
222,451 |
|
|
$ |
254,914 |
|
|
|
|
|
|
|
|
|
|
(In thousands) |
March 31, 2019 |
|
December 31, 2018 |
Assets: |
|
|
|
Pharmaceutical |
$ |
1,230,811 |
|
|
$ |
1,236,499 |
|
Diagnostics |
1,165,784 |
|
|
1,162,160 |
|
Corporate |
178,706 |
|
|
52,413 |
|
|
$ |
2,575,301 |
|
|
$ |
2,451,072 |
|
Goodwill: |
|
|
|
Pharmaceutical |
$ |
245,735 |
|
|
$ |
247,407 |
|
Diagnostics |
452,787 |
|
|
452,786 |
|
Corporate |
— |
|
|
— |
|
|
$ |
698,522 |
|
|
$ |
700,193 |
|
|